SAS Enterprise Guide 6.1: baseline characteristics presentation

Abstract

Objective: to develop algorithm of presentation of baseline characteristics of patients which enrolled in prospective non-randomized clinical trial AMIRI – CABG (ClinicalTrials.gov Identifier: NCT03050489).

Materials and methods. Data collection was performed according to prospective non-randomized clinical trial AMIRI — CABG in Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russia between 2016-2019 years with 336 patients. Patients were allocated into three groups of treatment. There is database with clinical, laboratory and instrumental data. Comparison for nominal data (gender and incidence of myocardial infarction and stroke) were calculated with SAS Enterprise Guide 6.1 software with Chi-squared test and exact Fisher test. Baseline characteristics were presented in table.

Results. There was developed algorithm of baseline characteristics presentation in APA-table.

Conclusion. There was developed algorithm of baseline characteristics presentation SAS Enterprise Guide 6.1 could be useful for manuscript preparing for Russian and foreign journal.

Keywords

SAS Enterprise Guide / Chi-squared test / exact Fisher test / baseline characteristics / data presentation

References

[1] Gu H-Q, Li D-J, Liu C, Rao Z-Z. %ggBaseline: a SAS macro for analyzing and reporting baseline characteristics automatically in medical research. Annals of Translational Medicine. 2018;6(16):326–326. DOI: 10.21037/atm.2018.08.13

[2] Gu H.-Q., Li D.-J., Liu C., Rao Z.-Z. %ggBaseline: a SAS macro for analyzing and reporting baseline characteristics automatically in medical research // Annals of Translational Medicine. 2018. Vol. 6, No. 16. P. 326–326. DOI: 10.21037/atm.2018.08.13

[3] Bunenkov NS, Bunenkova GF, Komok VV, et al. SAS enterprise guide 6.1 for physicians: multiple comparisons. Medical Academic Journal. 2019;19(4):33–40. (In Russ.). DOI: 10.17816/MAJ17736

[4] Буненков Н.С., Буненкова Г.Ф., Комок В.В. и др. SAS Enterprise Guide 6.1 для врачей: сравнение групп // Медицинский академический журнал. 2019. T. 19, № 4. C. 33–40. DOI: 10.17816/MAJ17736

[5] Bunenkov NS, Bunenkova GF, Komok VV, et al. SAS enterprise guide 6.1: independent groups comparison for nominal data. Medical Academic Journal. 2020;20(3):89–98. (In Russ.). DOI: 10.17816/MAJ34127

[6] Буненков Н.С., Буненкова Г.Ф., Комок В.В. и др. SAS Enterprise Guide 6.1: cравнение независимых групп по качественным признакам // Медицинский академический журнал. 2020. T. 20, № 3. C. 89–98. DOI: 10.17816/MAJ34127

[7] Bunenkov NS, Bunenkova GF, Beliy SA, et al. SAS enterprise guide 6.1 for physicians: getting started. Medical Academic Journal. 2019;19(3):27–36. (In Russ.). DOI: 10.17816/maj19327-36

[8] Буненков Н.С., Буненкова Г.Ф., Белый С.А. и др. SAS Enterprise Guide 6.1 для врачей: начало работы // Медицинский академический журнал. 2019. T. 19, № 3. C. 27–36. DOI: 10.17816/maj19327-36

[9] Vlasova II, Sokolov AV, Kostevich VA, et al. Myeloperoxidase-induced oxidation of albumin and ceruloplasmin: role of tyrosines. Biochemistry (Moscow). 2019;84(6):652–662. DOI: 10.1134/S0320972519060095

[10] Власова И.И., Соколов А.В., Костевич В.А. и др. Индуцированное миелопероксидазой окисление альбумина и церулоплазмина: роль тирозина // Биохимия. 2019. T. 84, № 6. C. 836–848. DOI: 10.1134/S0320972519060095

[11] Grigorieva DV, Gorudko IV, Kostevich VA, et al. Myeloperoxidase activity in blood plasma as a criterion of therapy for patients with cardiovascular disease. Biomeditsinskaya khimiya. 2016;62(3):318–324. (In Russ.). DOI: 10.18097/PBMC20166203318

[12] Григорьева Д.В., Горудко И.В., Костевич В.А. и др. Активность миелопероксидазы в плазме крови как критерий эффективности лечения пациентов с сердечно-сосудистыми заболеваниями // Биомедицинская химия. 2016. T. 62, № 3. C. 318–324. DOI: 10.18097/PBMC20166203318

[13] Panasenko OM, Mikhalchik EV, Sokolov AV, et al. The effects of antioxidants and hypohalous acid scavengers on neutrophil activation by hypochlorous acid-modified low-density lipoproteins. Biophysics. 2016;61(3):420–428.

[14] Панасенко О.М., Михальчик Е.В., Горудко И.В. и др. Влияние антиоксидантов и скавенджеров гипогалоидных кислот на активацию нейтрофилов липопротеинами низкой плотности, модифицированными гипохлоритом // Биофизика. 2016. T. 61, № 3. C. 500–509.

[15] Sokolov AV, Kostevich VA, Gorbunov NP, et al. A link between active myeloperoxidase and chlorinated ceruloplasmin in blood plasma of patients with cardiovascular diseases. Medical Immunology (Russia). 2018;20(5):699–710. (In Russ.). DOI: 10.15789/1563-0625-2018-5-699-710

[16] Соколов А.В., Костевич В.А., Горбунов Н.П. и др. Связь между активной миелопероксидазой и хлорированным церулоплазмином в плазме крови пациентов с сердечно-сосудистыми заболеваниями // Медицинская иммунология. 2018. T. 20, № 5. C. 699–710. DOI: 10.15789/1563-0625-2018-5-699-710

RIGHTS & PERMISSIONS

Bunenkov N.S., Komok V.V., Grudinin N.V., Bobylkov V.A., Bunenkova G.F., Grinenko O.A., Nemkov A.S.